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Role of Neuropoietic Cytokines in Development
and Progression of Diabetic Polyneuropathy: From Glucose
Metabolism to Neurodegeneration
Dusanka S. Skundric and Robert P. Lisak
Department of Neurology, Division of Neuroimmunology, and Department of Immunology
and Microbiology, Wayne State University School of Medicine, Detroit Medical Centre, Detroit,
Michigan, USA
Diabetic neuropathy develops as a result of hyper-
glycemia-induced local metabolic and microvascular
changes in both type I and type II diabetes mellitus. Diabetic
neuropathy shows slower impulse conduction, axonal de-
generation, and impaired regeneration. Diabetic neuropa-
thy affects peripheral, central, and visceral sensorimotor
and motor nerves, causing improper locomotor and vis-
ceral organ dysfunctions. The pathogenesis of diabetic neu-
ropathy is complex and involves multiple pathways. Lack
of success in preventing neuropathy, even with successful
treatment of hyperglycemia, suggests the presence of early
mediators between hyperglycemia-induced metabolic and
enzymatic changes and functional and structural proper-
ties of Schwann cells (SCs) and axons. It is feasible that
once activated, such mediators can act independently of the
initial metabolic stimulus to modulate SC-axonal communi-
cation. Neuropoietic cytokines, including interleukin-1 (IL-
1), interleukin-6 (IL-6), leukemia inhibitory factor (LIF),
ciliary neurotrophic factor (CNTF), tumor necrosis factor
alpha (TNF-α), and transforming growth factor beta (TGF-
β), exhibit pleiotrophic effects on homeostasis of glia and
neurons in central, peripheral, and autonomic nervous sys-
tem. These cytokines are produced locally by resident and
infiltrating macrophages, lymphocytes, mast cells, SCs, fi-
broblasts, and sensory neurons. Metabolic changes induced
by hyperglycemia lead to dysregulation of cytokine control.
Moreover, their regulatory roles in nerve degeneration and
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regeneration may potentially be utilized for the prevention
and/or therapy of diabetic neuropathy.
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INTRODUCTION
Diabetic polyneuropathy is a chronic complication of both
type I and type II diabetes mellitus. It affects peripheral, cen-
tral, and visceral sensorimotor and motor nerves. Diabetic neu-
ropathy develops as a result of hyperglycemia-induced local
metabolic and microvascular changes. Chronic complications,
including neuropathy, retinopathy, and nephropathy, are major
causes of morbidity and mortality in patients with type I and
type II diabetes (review by Sheetz and King, 2002; Williams
et al., 2002).
In peripheral nerve, abnormalities of the Na+ and K+ trans-
port along myelinated axons lead to impairment of the nerve
function. Insufficient function of the peripheral nerve is mani-
fested as slower conduction velocity, which develops early af-
ter the onset of diabetes. This early functional abnormality is
followed by more pronounced changes in the morphology of
Schwann cells (SCs), axons, and sensory neurons, which ulti-
mately lead to axonal degeneration. Studies from experimental
models that resemble the patterns of human pathology provide
insights into the metabolic and molecular pathways underly-
ing diabetic neuropathy (Sima et al., 2000, Sima, 2001; review
by Eckersley, 2002). Homeostasis of myelinated peripheral
nerve fibers is maintained through the SC-axonal contacts and
communications. This includes, but is not limited to, production
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of neuropoietic cytokines and neurotrophic factors, expression
of cell adhesion molecules (CAMs) and deposition of extra-
cellular matrix (ECM) by SCs. In diabetic neuropathy, many
aspects of SC-axonal communication are compromised. Dis-
turbed local homeostasis leads to axonal degeneration accom-
panied by impaired ability to regenerate (Xu et al., 2002). Con-
ventional therapy of diabetes and maintenance of euglycemic
levels combined with auxiliary therapies to increase perfusion
and/or prevent aberrant pathways of glucose metabolism have
failed to halt and/or restore functional and structural changes
of peripheral nerve, in both humans and experimental ani-
mals. This striking lack of success in preventing neuropathy,
even with successful treatment of hyperglycemia, suggests the
presence of early mediators between hyperglycemia-induced
metabolic and enzymatic changes and functional and structural
properties of SCs and axons. It is feasible that once activated,
such mediators can act independently of the initial metabolic
stimulus to modulate SC-axonal communication. Partial suc-
cess of some therapies in abrogating signs of already devel-
oped diabetic neuropathy argues against the development of
completely irreversible changes, and provides hope for the dis-
covery of novel therapies targeting early factors involved in
pathogenesis of diabetic neuropathy. It is clear that the patho-
genesis of diabetic neuropathy is complex and involves mul-
tiple pathways. Therefore, early therapeutic intervention with
combined therapies aimed at modulation and/or blocking of
aberrant pathways might prove to be beneficial in the preven-
tion and/or reversal of diabetic neuropathy. Such an approach
is further emphasized by findings that combined blocking of
several pathways, independently induced by high glucose, is
needed for restoration of the metabolic abnormalities that un-
derlie microvascular complications in diabetes. This therapeu-
tic strategy has proved successful in the treatment of experi-
mental diabetic retinopathy (Nishikawa, 2000; Hammes et al.,
2003).
In this article we will briefly summarize major properties of a
specific group of mediators called neuropoietic cytokines within
the peripheral nervous system (PNS) and present evidence for
their role in the regulation of homeostasis, glucose metabolism,
degeneration, and regeneration of the peripheral nerve. Neu-
ropoietic cytokines, including interleukin-1 (IL-1), interleukin-
6 (IL-6), leukemia inhibitory factor (LIF), ciliary neurotrophic
factor (CNTF), tumor necrosis factor alpha (TNF-α) and trans-
forming growth factor beta (TGF-β), are potent regulators of
homeostatic properties of peripheral nerve. These cytokines
are produced locally by resident and infiltrating macrophages,
lymphocytes, mast cells, SCs, fibroblasts, and sensory neurons.
Metabolic changes induced by hyperglycemia lead to dysregu-
lation of cytokine control.
METABOLIC CHANGES IN THE DIABETIC
PERIPHERAL NERVE
Elevated blood glucose levels activate aberrant pathways of
glucose metabolism, such as the polyol pathway. Activation of
such metabolic pathways leads to accumulation of their specific
end products, such as sorbitol and fructose, and secondarily
perturbs phosphoinositide turnover and diacylglycerol (DAG),
which in turn may directly or indirectly cause damage to glia and
neurons. Furthermore, local accumulation of these end products
induces changes in cell signaling in glia and neurons, perturbing
various homeostatic functions regulated by those cell-signaling
pathways (review by Sheetz and King, 2002).
The hallmarks of glucose metabolism through the polyol
pathway are activation of the enzyme aldose reductase (AR) and
accumulation of sorbitol. Depending on its intracellular concen-
tration, sorbitol may have either toxic or hyperosmotic effects
on cells. Increased intracellular osmotic pressure, together with
perturbed balances and exchange of cations and anions, affects
transcription of numerous genes, including genes of proinflam-
matory cytokines IL-1, IL-6, and TNF-α. However, therapies
aimed at inhibiting AR used for the treatment and/or preven-
tion of diabetic neuropathy in humans have failed to achieve
desired effects. Similar therapies, if started early in different
animal models of diabetic neuropathy, have, however, shown
promising results in ameliorating neuropathy (review by Sima,
2001; Simmons and Feldman, 2002).
Hyperglycemia leads to accelerated phosphoinositide
turnover, activation of phospholipase D and changes of DAG
levels (Sugimoto et al., 2000). Although hyperglycemia in
peripheral nerve leads to overall impaired phosphoinositide
turnover, DAG accumulation and total protein kinase C (PKC)
expression (Eichberg, 2000), there is evidence to suggest that
vascular PKC-β isoforms are increased in diabetic nerve. Ac-
tivated phospholipase D and DAG induce changes in the ac-
tivation of PKC and expression of its isoforms in peripheral
nerve. Changes in PKC activation and/or PKC isoform ex-
pression can modulate the activity of Na+, K+-ATPase. The
Na+,K+-ATPase pump actively regulates intracellular concen-
trations of these two cations important for the function of
cellular enzymes and transcription factors, such as activator
protein-1 (AP-1) and nuclear factor kappa B (NF-κB). Tran-
scription factors AP-1 and NF-κB are involved in the initia-
tion of the transcription of numerous genes, including proin-
flammatory and neuropoietic cytokines (IL-1, IL-6, TNF-α).
In SCs, stimulation of PKC through extracellular signal regu-
lated kinase (ERK) activation regulates the levels of LIF mRNA
(Nagamoto-Combs et al., 1999). Neuropoietic cytokines have
pleiotrophic effects on glia and neurons, either directly or
indirectly through regulation of neurotrophic factors. The
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binding of cytokines to the gp130 receptor activates the signal
transducer and activators of transcription 3 (STAT3), mitogen-
activated protein kinase (MAPK), MAPK kinase (MEK), phos-
phatidylinositol 3-kinase (PI3K), and serine/threonine kinases
called Akt (protein kinase B) signaling pathways. These signal-
ing pathways play important roles in the regulation of cellular
glucose metabolism and cell survival. STAT3 and PI3K/Akt sig-
naling play major roles in mediating the survival response of
neurons to cytokines (Alonzi et al., 2001). The same signaling
pathways may be activated by insulin itself and synergistically
so by C-peptide (Grunberger et al., 2001; Li et al., 2002).
Lack of neurotrophic support by nerve growth factor (NGF),
neurotropin-3 (NT-3), brain-derived nerve factor (BDNF),
insulin-like growth factor-I (IGF-I), and vascular endothelial
growth factor (VEGF) is implicated in apoptosis of dorsal
root ganglia sensory neurons and axonal degeneration in di-
abetes (Thrailkill, 2000; Carmeliet and Storkebaum, 2002;
Nitta et al., 2002). Systemic therapies aimed to supplement
local trophic factor deficiency have shown limited or no ef-
fects (Pradat et al., 2001; Wellmer et al., 2001) in the pro-
tection and/or repair of diabetic peripheral nerve. In vitro ex-
periments in which SCs were cultured in the presence of el-
evated glucose concentration revealed alterations in arachi-
donic acid metabolism. Decreased content of glycerophos-
pholipid arachidonoyl-containing molecular species (ACMS),
decreased free cytosolic nicotinamide adenine dinucleotide
(NAD+/NADH), increased malondialdehyde, depleted glu-
tathione levels, and reduced cytosolic superoxide dismutase
activity suggest that high glucose level elicit oxidative stress
in SCs cultures (Miinea et al., 2002; Vincent et al., 2002). Ox-
idative stress and inflammatory cytokines influence the bidirec-
tional relationship between iron metabolic pathways and glu-
cose metabolism, amplifying and potentiating hyperglycemia-
induced events (Fernandez-Real et al., 2002). In peripheral
nerve, cytokines regulate functions essential for SC-axonal
homeostasis and nerve regeneration, such as production of
ECM, expression of CAMs, and organization of the cytoskele-
ton (Chandross et al., 1996). Lack of CAM expression by
SCs and/or dysregulation of ECM production and deposi-
tion by SCs lead to improper contact between SCs and ax-
ons (Stewart et al., 1997). If not corrected, these abnormal-
ities may cause degenerative changes such as fiber loss and
perinodal demyelination (Fu and Gordon, 1997). Regulation
of Na+ and K+ voltage-gated channel expression and func-
tion by proinflammatory cytokines has been reported in cen-
tral nervous system (CNS) (Vega et al., 2002). The exis-
tence of similar mechanisms in peripheral nerve and their
relevance for impulse propagation remain to be investigated
(Figure 1).
NEUROPOIETIC CYTOKINES: ROLE IN
HOMEOSTASIS, DEGENERATION, AND
REGENERATION OF PERIPHERAL NERVE
AND RELATION TO GLUCOSE METABOLISM
Neuropoietic cytokines from the IL-1 and IL-6 families,
TNF-α, and TGF-β exhibit pleiotrophic effects on glia cells and
neurons important for the homeostasis of the peripheral, cen-
tral, and autonomic nervous systems (Armati and Pollard, 1996;
Benveniste, 1998; Chalazonitis et al., 1998; Charon et al., 1998;
Geissen et al., 1998; Horton et al., 1998; Lisak et al., 1997). In
this section, we will focus on cytokines produced locally by
SCs and/or sensory neurons in the PNS and their effects on reg-
ulation of homeostasis and degeneration and regeneration of
peripheral nerve. The effects of cytokines on similar functions
in the CNS and autonomic nerves have been studied to a lesser
extent.
Cytokines produced in peripheral nerve originate from res-
ident and infiltrating macrophages, lymphocytes, mast cells,
SCs, fibroblasts, and probably neurons. Cytokines are involved
in the pathogenesis of nerve damage as well as repair. For ex-
ample, TNF-α injected into nerve induces inflammatory de-
myelination and wallerian degeneration, whereas IL-1 produc-
tion promotes phagocytosis by scavenger macrophages and the
synthesis of neurotrophic factors nerve growth factor (NGF)
and LIF (Lindholm et al., 1987; Carlson et al., 1996). After
experimental axotomy, other neuropoietic cytokines, including
IL-6, LIF, and TGF-β1, are overexpressed in nerve and pro-
mote axonal growth until the contact with SCs is established.
Proinflammatory cytokines are instrumental to the course
of inflammatory demyelinating neuropathies. They increase
vascular permeability of the blood-nerve barrier, which favors
transmigration of leukocytes into nerve. They induce activa-
tion and proliferation of lymphocytes and macrophages and
may have a direct myelinotoxic activity. In addition, down-
regulation of the immunosuppressive cytokine TGF-β1 may
favor the nerve inflammatory reactions (reviewed by Creange
et al., 1997).
Mechanisms leading to nerve degeneration and regenera-
tion are essential in the pathogenesis of diabetic neuropathy.
Compared to normal, the ability of diabetic peripheral nerve
to regenerate is significantly diminished (Cameron and Cotter,
1997). In a comparative analysis, Pierson et al. (2003) found
that regenerative potentials in type I are affected to a greater
extent than in type II diabetic neuropathy. The regulatory roles
of cytokines in nerve degeneration and regeneration may po-
tentially be utilized for the prevention and/or therapy of di-
abetic neuropathy. Prior to attempting cytokine-based therapy,
one needs to understand the effects of long-term hyperglycemia
on the local cytokine network. Data are still lacking regarding
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FIGURE 1
Schematic diagram of major aberrant metabolic pathways induced by hyperglycemia. The proposed role of proinflammatory
cytokines in relation to metabolic end products, activated enzymes, transcription factors, neuropoietic cytokines, and molecules
involved in Schwann cell–axonal communication.
the mechanisms involved in cytokine regulation by long-term
hyperglycemia in peripheral nerve. Therefore, this review will
focus on bringing together existing knowledge about major reg-
ulatory properties of neuropoietic cytokines in nerve degener-
ation and regeneration, and how these may be of relevance for
diabetic neuropathy. Each cytokine family will be discussed
separately because of many shared properties within family
members. Some properties are shared between different cy-
tokines and therefore cytokine redundancy plays an important
role in the local cytokine network. Finally we will incorporate
data from studies on cytokine regulation in diabetic neuropathy,
which are still sparse but emerging. In different experimental
models of diabetic neuropathy, only a handful of laboratories,
including ours, have directly studied the regulation of cytokines
and its role in the pathogenesis of diabetic neuropathy. There-
fore, for the most part, we will summarize data from differ-
ent models of nerve degeneration and regeneration, which are
relevant to diabetic neuropathy, attempting to underscore the
significance of further understanding of cytokine regulation in
similar processes pertaining to diabetic neuropathy.
Autocrine Regulation of IL-1 in Peripheral
Nerve: Role in Homeostasis, Regeneration
and the Pathogenesis of Diabetic Neuropathy
The SC is the myelin-producing glia of the PNS. It is respon-
sible for myelination and ensheathment of myelinated periph-
eral nerve, fibers. SCs also provide trophic support for neuronal
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cells by regulation of neurotrophin, production in both normal
and pathologic states. IL-1 is a proinflammatory and neuropoi-
etic cytokine, locally produced by SCs, endoneurial and infil-
trating macrophages and fibroblasts in peripheral nerve, and
sensory neurons in dorsal root ganglia (Lisak et al., 1997). IL-1
regulates the production of other cytokines, neurotrophins, and
pain mediators by SCs and sensory neurons (Shadiack et al.,
1993). IL-1 induces production of NGF (Lindholm et al., 1987).
Operating as autocrine and paracrine factors, locally produced
proinflammatory cytokines, including IL-1, IL-6 and TNF-α,
interact through a cytokine-specific network in the PNS. Consti-
tutive expression of IL-1α, IL-1β, interleukin beta–converting
enzyme (ICE, caspase-1), and type I IL-1 receptor (IL-1RI) has
been detected in normal adult sciatic nerve. Proinflammatory
cytokines are up-regulated by peripheral nerve injury, includ-
ing contusion, transection, toxicity, autoimmune, and metabolic
insults. Rapid up-regulation of cytokines following injury to pe-
ripheral nerve precedes macrophage infiltration and secretion of
other products of inflammation. IL-1 is especially important for
the regulation of macrophage chemoattraction by stimulation
of macrophage chemoattractant protein-1 (MCP-1, CCL2) by
SCs. SCs of denervated nerves attract macrophages by secretion
of MCP-1 in a process regulated by IL-6 and LIF (Tofaris et al.,
2002). LIF mRNA is virtually undetectable in uninjured sensory
neurons but is induced by the inflammatory cytokine IL-1. Bio-
logical properties of IL-1 are mediated through IL-1RI, which
has been suggested to stimulate a ceramide-dependent protein
kinase pathway, much like TFN-α (Dinarello and Thompson,
1991) IL-1 regulation of LIF mRNA, through stimulation of
the endosomal, acidic sphingomyelinase pathway, leads to ce-
ramide activation of PKC zeta (Carlson and Hart, 1996). IL-
1β induction of LIF gene expression is at least partially tran-
scriptional, but LIF mRNA increases to a greater extent than
LIF transcription, suggesting a post-transcriptional regulation
as well (Carlson et al., 1996).
IL-1β, IL-6, and LIF affect dorsal root ganglia neurons in
terms of survival or neuritogenesis. Some of the effects are in-
direct, probably mediated by NGF (Edoff and Jerregard, 2002).
SCs regulate IL-1 production in an autocrine manner. They
produce both IL-1α and IL-1β and a natural antagonist, IL-
1 receptor antagonist (IL-1RA). SCs also express IL-1R I, a
biologically active IL-1 receptor (Skundric et al., 1997).
The ability of SCs to autoregulate IL-1 is activated in lo-
cal immune regulation during autoimmune demyelinating neu-
ritis (Figure 2) (Skundric et al., 2001). We investigated IL-1
autoregulation in sciatic nerves of BB/W spontaneously dia-
betic rats throughout the course of diabetic neuropathy. Our
results showed activation of IL-1 signaling pathway in SCs,
prior to and during the early stages of diabetic neuropathy, thus
suggesting a role in the initiation of abnormal SC-axonal in-
teraction (Skundric et al., 2002a). Activation of ICE (caspase-
1) corresponded to up-regulation of IL-1β production and re-
cruitment of IL-1 receptor associated kinase (IRAK) by SCs
at the early stages of neuropathy. Moreover, activation of IL-1
signaling was occurring concomitantly with activation of IκB
and subsequent translocation of NF-κB p65 in SCs (Skundric
et al., 2002a). Activation of IL-1 signaling pathway may im-
pact on the regulation of other proinflammatory cytokines in
diabetic nerve. It may also be involved in the regulation of
oxidative metabolism through regulation of inducible nitric
oxide synthase (iNOS) and therefore reactive oxygen species
(ROS). Oxidative stress has been recently proposed as a mecha-
nism responsible for apoptosis induction in diabetic neuropathy
(Vincent et al., 2002).
Taken together, IL-1 is a potent regulator of both homeo-
static mechanisms relevant for peripheral nerve function and
IL-1 signaling, involved in pathogenic mechanisms implicated
in the development of diabetic neuropathy. Activation of IL-1
signaling in diabetic nerve may thus represent initial compen-
satory effects and, if sustained, may contribute to ongoing de-
generation. Future experiments designed to examine functional
and structural changes in diabetic nerve induced by local mod-
ulation of IL-1 signaling are needed to explore these potential
effects. The IL-1 cytokine family and components of IL-1–
specific signaling cascade have been thoroughly described and
many transgenic mice models have been generated to facilitate
the study of IL-1 pathways. Unfortunately, the utilization of
transgenic mice is of limited use for experiments required to
understand the role of IL-1 in diabetic neuropathy. Such ex-
periments have been mainly hampered by the significant role
of proinflammatory cytokines in the pathogenesis of type I di-
abetes. Therefore, strategies to modulate cytokine production
and signaling locally need to be explored. Such approaches are
feasible in the case of IL-1; the basis for experimental therapies
may include local use of the natural antagonist IL-1RA, specific
signaling blockers, and IL-1–specific traps.
NEUROPOIETIC PROPERTIES OF IL-6, LIF,
AND CNTF: REGULATION IN DIABETIC
NERVE
IL-6, CNTF, LIF, and cardiotrophin-1 (CT-1) comprise a
group of structurally related cytokines that promote the sur-
vival of subsets of neurons in the developing peripheral ner-
vous system through activation of transcription factor NF-κB
(Middleton et al., 2000). Constitutive expression of IL-6, IL-6
receptors, and the signaling protein of the IL-6 receptor, gp130,
suggests a role in the homeostasis of the peripheral nerve. IL-6 is
induced in peripheral nerve following injury and it is produced
by SCs (Bolin et al., 1995). The role of neuropoietic cytokines
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FIGURE 2
Schematic diagram presenting IL-1 autoregulation by Schwann cells, macrophages (Mo), and T lymphocytes (Th1) in the
peripheral nerve during experimental autoimmune neuritis (EAN).
of the IL-6 family in the homeostasis and regeneration of the
peripheral nerve can be modulated by neurotrophins. This reg-
ulation is bidirectional and influences the regenerative ability
of the peripheral nerve. For example, NGF inhibits sympathetic
neurons’ response to LIF through regulation of injury-induced
molecules, such as galanin. Galanin expression is triggered by
two consequences of nerve transection: the induction of LIF
and the reduction in the availability of the target-derived factor,
NGF (Shadiack et al., 1998). Similarly, damage-induced neu-
ronal endopeptidase (DINE/ECEL) expression is regulated by
LIF induction and deprivation of NGF in rat sensory ganglia
after nerve injury (Kato et al., 2002).
In human chronic inflammatory demyelinating polyneu-
ropathy (CIDP), multiple neurotrophic growth factors and
cytokines, NGF, glial cell line-derived neurotrophic factor
(GDNF), LIF, and IL-6, are expressed together with their con-
comitant receptors in the nerve lesions and play an important
role particularly in nerve repair (Yamamoto et al., 2002). The
fact that the expression of neuropoietic cytokines and their re-
ceptors correspond to similarities in pathologic, events, rather
than a specific disease, is clear from analyses of various hu-
man peripheral neuropathies (Ito et al., 2001). LIF appears to
regulate IGF-I expression in the peripheral nerve in the basal
state and early in the regeneration response in vivo (de Pablo
et al., 2000). There is no direct evidence that LIF and CNTF
are regulated by hyperglycemia. Future studies should reveal if
mechanisms of LIF and CNTF regulation in diabetic neuropa-
thy correspond to patterns observed in other degenerative and
demyelinating neuropathies. Such data, combined with known
mechanisms of neurotrophic factor regulation in diabetic neu-
ropathy, may be useful in considering combined therapies aimed
at ameliorating degeneration and improving regeneration of di-
abetic nerve.
Our results from gene array analysis of BB/W rats, which
spontaneously develop type I diabetes accompanied with di-
abetic neuropathy, showed concomitant down-regulation of
voltage-gated Na+ channel β subunits with IL-6 expression
and signaling through STAT3 at early stages of diabetic neu-
ropathy (Skundric et al., 2002b; Sima et al., 2003). Similar
down-regulation of Na+ channel β subunits was observed
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in SCs cultured in hyperglycemic condition. Levels of Na+
channel β2 and β3 subunits were recovered by addition of IL-6
to SCs cultures (Skundric et al., 2002c). These subunits play
important roles as CAMs and in distribution and anchoring
of voltage-gated Na+ channels at the nodal axolemma (Isom,
2002; Sima et al., 2003). Lateralization of voltage-gated Na+
channels from the node and their spreading to the juxtapara-
nodal and internodal regions have been observed in diabetic
nerves of rats with type I diabetes (Cherian et al., 1996). There-
fore, the potential of IL-6 to restore β-subunit expression may
provide a basis for modulation of two processes essential for
peripheral nerve integrity: one, related to voltage-gated Na+
channel anchoring in the membrane and, second, CAM expres-
sion by SCs. IL-6 may play an important role in reestablish-
ing CAM expression and binding to appropriate ECM ligands,
which is profoundly perturbed in diabetic nerve (Merry et al.,
1998) (see Figure 1). Proper contact between SCs through CAM
expression with ECM is necessary for SC-axonal homeostatic
communication. We also found that IL-6 exhibits the potential
to regulate the expression of Na+,K+-ATPase in cultured SCs
(Skundric, unpublished data). These findings underscore the
significance of understanding the mechanisms of IL-6–specific
regulation of voltage-gated Na+ channels and Na+,K+-ATPase
in peripheral nerve. Future experiments will be required to re-
veal if IL-6 modulates expression of only β subunits, with
CAM-like properties, or if it also affects the expression and
function of α subunits, directly engaged in Na+ and K+ trans-
port. A recent report from Sima et al. (2003) suggests lack
of significant differences in expression levels of α subunits of
voltage-gated Na+ channels in diabetic neuropathy in rats.
Role of TNF in Peripheral Nerve Degeneration,
Apoptosis, and Glucose Metabolism
Experiments in mice with genetically distinct patterns of
wallerian degeneration show that TNF-α and IL-1α initiate
molecular and cellular events in rapid-wallerian degeneration
(e.g., the production of additional cytokines and NGF). TNF-α,
IL-1α, and IL-1β may further regulate indirectly macrophage
recruitment, myelin removal, regeneration, and neuropathic
pain. In contrast to rapid-wallerian degeneration, production of
TNF-α, IL-1α, and IL-1β proteins is deficient in slow-wallerian
degeneration, although their mRNAs are expressed. mRNA ex-
pression and protein production of TNF-α, IL-1α, and IL-1β
are differentially regulated during rapid-wallerian degeneration
(normal) and slow-wallerian degeneration (delayed), suggest-
ing that mRNA expression by itself is not an indication of the
functional involvement of cytokines in wallerien degeneration
(Shamash et al., 2002).
IL-1α and TNF-α markedly stimulate glucose utilization in
primary cultures of mouse cortical astrocytes. PI3K is essen-
tial for the effect of both IL-1α and TNF-α, whereas the action
of IL-1α also requires activation of the MAP kinase pathway.
The Na+,K+-ATPase inhibitor ouabain prevents the IL-1α– and
TNF-α–stimulated 2-deoxyglucose (2DG) uptake. These data
suggest that Na+ pump activity is a common target for the
long-term metabolic action of cytokines, promoted by the ac-
tivation of distinct signaling pathways (Vega et al., 2002). In
cultured myocytes, TNF-α decreased fatty-acid transport pro-
tein 1 (FATP-1) mRNA, insulin receptor substrate-1 (IRS-1)–
associated PI3K activity, and glucose uptake, resulting in severe
diet-induced insulin resistance (Maeda et al., 2002).
TNF-α is locally produced by SCs and has a role in periph-
eral nerve regeneration and regulation of apoptosis (Armati
and Pollard, 1996). Our analysis of diabetic sciatic nerves in
the spontaneously diabetic BB/W rat revealed up-regulation
of TNF-α as well as initiator and executive caspases at early
stages of diabetes. Activation of one of the major executive
caspases, caspase-3, was observed. These findings suggest a
role of TNF-α in regulation of apoptosis in diabetic neuropathy
(Skundric et al., 2003). Mitochondrial dysfunction and apop-
tosis play important roles in the pathogenesis of diabetic neu-
ropathy (Srinivasan et al., 2000). Revealing the mechanisms
of TNF-α–specific modulations of degeneration, regeneration,
and apoptosis in diabetic peripheral nerve will significantly fos-
ter the development of appropriate therapies aimed to control
these processes locally. TNF-α is a good candidate to be consid-
ered as a possible therapeutic target because of the availability
of TNF-α family proteins, soluble receptors, and blockers of
some signaling components. TNF-α–related therapies have al-
ready been used in treatment of other neurodegenerative and
inflammatory processes.
Role of TGF-β in the Cytokine-Specific
Network in Peripheral Nerve: Implication
for Diabetic Neuropathy
The TGF-β family of cytokines is involved in multiple path-
ways regulating SC and neuronal development, SC prolifera-
tion, production of neurotrophic factors, ECM deposition, and
expression of CAMs.
Treatment with TGF-β1 leads to induction of LIF mRNA
in cultured SCs. This effect is mediated through PKC. The ef-
fect of TGF-β1 on LIF induction is abrogated by experimental
conditions favoring SC-neuronal contact and myelination. This
indicates that following lesions of peripheral nerve, SCs could
respond to TGF-β1 by producing LIF, which in turn has neuro-
protective effect and promotes regeneration. Once SC-axonal
contact is established, effect of TGF-β on LIF production sub-
sides (Matsuoka et al., 1997). In contrast to induction of LIF,
TGF-β has negative regulatory effect on the production of NT-3
mRNA at the site of peripheral nerve injury (Cai et al., 1999).
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TGF-β plays a role in SC communication with ECM by reg-
ulating alpha1beta1 integrin expression (Stewart et al., 1997).
Binding of alpha1beta1 integrin, expressed by SC, to ECM
ligands laminin/collagen, plays an essential role in SC devel-
opment and differentiation. In regard to sensory neuronal de-
velopment, endogenous TGF-β plays a significant role in regu-
lation of ontogenetic neuron death. Experiments in developing
chick embryo showed proapoptotic effects of TGF-β signaling
on ontogenetic death of sensory and motor neurons. These ex-
periments suggest a similar role of TGF-β in neuronal death
in a situation of target deprivation (Krieglstein et al., 2000).
TGF-β1 and TNF-α induce SC death by apoptosis (Skoff et al.,
1998). TGF-β also exhibits effect on SC differentiation (Lisak
et al., 2001). Similar role for TGF-β, in control of develop-
mentally regulated apoptosis of the SC lineage, has been de-
scribed. This role is executed via TGF-β–specific phospho-
rylation of the early response gene c-Jun in nondifferentiated
SCs, whereas more differentiated SCs are protected from this
mechanism (Parkinson et al., 2001). In relation to SC plasticity,
which is critical for peripheral nerve regeneration, TGF-β has
beneficial effect by supporting the proliferating SC phenotype
involved in axonal regeneration. It is important that supportive
effects of TGF-β on axonal regeneration overcome the nega-
tive effects of long-term SC denervation (Sulaiman and Gordon,
2002). Specific up-regulation of TGF-β, its receptors (type I and
type II), and intracellular second messengers, Smad 2/3 and 4,
was observed in sensory neurons and satellite cells of dorsal
root ganglia following injury (Stark et al., 2001). Future exper-
iments designed to reveal the molecular mechanisms of TGF-β
regulation in diabetic nerve are needed in order to explore the
potential therapeutic utilization of TGF-β in the prevention and
treatment of diabetic neuropathy.
CONCLUSION AND FUTURE DIRECTIONS
Diabetic polyneuropathy is a chronic debilitating complica-
tion of both type I and type II diabetes mellitus. It develops as a
result of hyperglycemia-induced local metabolic and microvas-
cular changes. Neuropathy affects peripheral, central, and vis-
ceral sensorimotor and motor nerves and causes impairment of
locomotor system and visceral organs. Neuropathy, along with
other chronic complications, is the leading cause of morbidity
and mortality of diabetes patients.
The pathogenesis of diabetic neuropathy is complex and in-
volves multiple pathways. Therefore, early therapeutic inter-
vention with combined therapies aimed at modulation and/or
blocking of aberrant pathways might prove to be beneficial in
the prevention and/or reversal of diabetic neuropathy.
Neuropoietic cytokines from the IL-1 and IL-6 families,
TNF-α, and TGF-β exhibit pleiotrophic effects on glia cells and
neurons important for the homeostasis of the peripheral, central,
and autonomic nervous systems. Cytokines regulate degener-
ation and regeneration of peripheral nerve, processes essential
in the pathogenesis of diabetic neuropathy. The contribution of
cytokines to homeostasis and repair is mediated through nu-
merous functions, including regulation of neurotrophic factors,
ECM, CAMs, and SC proliferation and differentiation.
The regulatory roles of cytokines in nerve degeneration
and regeneration may potentially be utilized for the preven-
tion and/or therapy of diabetic neuropathy. Prior to attempting
cytokine-based therapy, one needs to understand the effects of
long-term hyperglycemia on the local cytokine network. Neu-
ropoietic cytokines and components of their specific signal-
ing cascade have been thoroughly described and many trans-
genic mice models have been generated to facilitate the study
of cytokine-specific pathways. Unfortunately, the utilization of
transgenic mice is of limited use for experiments required to
understand their role in diabetic neuropathy. Such experiments
have been hampered mainly by the significant role of proin-
flammatory cytokines in the pathogenesis of type I diabetes.
Therefore, strategies to modulate cytokine production and sig-
naling locally need to be explored. Such approaches are feasible
in the case of IL-1, IL-6, and TNF-α. The basis for experimental
therapies may include local use of the natural antagonists, solu-
ble receptors, blocking antibodies, specific signaling blockers,
and specific cytokine traps.
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